<DOC>
	<DOCNO>NCT02892565</DOCNO>
	<brief_summary>The purpose determine hypercoagulable phenotype thrombinography associate increase risk symptomatic objectively confirm first venous thrombotic event . This case-control study population patient systemic lupus erythematosus ( SLE ) and/or antiphospholipid antibody ( APL ) . Secondary purpose : 1 . To determine frequency hypercoagulable phenotype study population ; 2 . To analyze sensibility : consequence variation hypercoagulable phenotype threshold importance risk ; 3 . To identify ( genetic ) factor hypercoagulable phenotype frequency different group .</brief_summary>
	<brief_title>Hypercoagulable Phenotype Thrombinography ( Presence C Protein Dynamic Inhibitory System )</brief_title>
	<detailed_description />
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Venous Thrombosis</mesh_term>
	<mesh_term>Antiphospholipid Syndrome</mesh_term>
	<mesh_term>Thrombophilia</mesh_term>
	<criteria>Cases : Patients SLE and/or APL first document deep vein thrombosis episode ( minimum 6 month , maximum 6 year ) Any weight height Absence current anticoagulant treatment possibility platelet function inhibitory treatment ; actual guideline suggest longterm anticoagulant treatment patient first episode venous thrombosis APL ; however , patient study one circumstance : 1/ `` inconvenient '' stop patient , 2/ aspirin decide doctor prolong treatment Controls : Patients SLE and/or APL without thrombosis ( venous arterial ) Any weight height Possibility platelet function inhibitory treatment ( primary prophylaxis arterial manifestation ) Cases Controls : Pregnancy Refusal consent Difficulty followup ( sufficient motivation )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>systemic lupus erythematosus</keyword>
	<keyword>antiphospholipid syndrome</keyword>
	<keyword>antiphospholipid antibody</keyword>
</DOC>